GeoVax Live Webcast

Tonight, Monday at 5:30 PM. And You Don’t Fly to Newport Beach and Deal With all the Drinking, Investment Bankers, and Hedge Fund Managers, with all Pretty Girls Running Around.


One of our favorite long-term candidates’ continued weakness, now places GeoVax (GOVX) at the top of our list for medium-term (now to 1 year out) performance potential. The term ‘locked-and-loaded’ comes to mind.

it’s at events like this, that GeoVax could find a large investor like Unicycive (UNCY) did just four days ago, when they banked $50 million from Octagon Capital and Great Point Partners. the shares jumped 28% on the news of the funding.

While some uninformed investors may complain of ‘dilution,’ more experienced long-term investors get a confidence boost, as they understand the funding is the fuel to get the company to the finish line. So instead of the risk going up a notch, it actually goes down a notch (or two). Funding also attracts additional institutional investors. Been there, done that. If anything, we get nervous when companies don’t get funded!

The CEO presenting is brilliant, take a listen!

GeoVax to Present at the 36th Annual Roth Conference


Killer, 44-Page Report on GeoVax (GOVX).


No, we still don’t know how to pronounce the name, but were up 170% in little more than a year and we are only in the third inning, so were not complaining! It too, like GeoVax, was hitting new lows when we added it to the Watch List.

Adding Unicycive (UNCY) $0.75 to the Watch List.

Unicycive Announces $50 Million Private Placement


UNCY: The securities to be issued in connection with the private placement described above are being offered in a private placement under Section 4(a)(2) of the Securities Act of 1933, as amended (the “Act”), and Regulation D promulgated thereunder and have not been registered under the Act or applicable state securities laws. Accordingly, such securities may not be offered or sold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration requirements of the Act and such applicable state securities laws. Unicycive has agreed to file a registration statement with the Securities and Exchange Commission registering the resale of the shares of common stock issued in this private placement.

This press release shall not constitute an offer to sell or a solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

For further information, please see the Company’s current report on Form 8-K to be filed with the Securities and Exchange Commission.

Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified using words such as “anticipate,” “believe,” “forecast,” “estimated” and “intend” or other similar terms or expressions that concern Unicycive’s expectations, strategy, plans or intentions. Such forward-looking statements include, but are not limited to, statements regarding management’s beliefs regarding the use of proceeds of the private placement and the timing, size and completion of the private placement. These forward-looking statements are based on Unicycive’s current expectations and actual results could differ materially. There are several factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, clinical trials involve a lengthy and expensive process with an uncertain outcome, and results of earlier studies and trials may not be predictive of future trial results; our clinical trials may be suspended or discontinued due to unexpected side effects or other safety risks that could preclude approval of our product candidates; risks related to business interruptions, including the outbreak of COVID-19 coronavirus, which could seriously harm our financial condition and increase our costs and expenses; dependence on key personnel; substantial competition; uncertainties of patent protection and litigation; dependence upon third parties; and risks related to failure to obtain FDA clearances or approvals and noncompliance with FDA regulations. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the uncertainties related to market conditions and other factors described more fully in the section entitled ‘Risk Factors’ in Unicycive’s Annual Report on Form 10-K for the year ended December 31, 2022, and other periodic reports filed with the Securities and Exchange Commission. Any forward-looking statements contained in this press release speak only as of the date hereof, and Unicycive specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.

Investor Contact:

[email protected]
(650) 900-5470

SOURCE: Unicycive Therapeutics, Inc.


Forward-Looking Statements This post contains forward-looking statements regarding GeoVax’s business plans. The words “believe,” “look forward to,” “may,” “estimate,” “continue,” “anticipate,” “intend,” “should,” “plan,” “could,” “target,” “potential,” “is likely,” “will,” “expect” and similar expressions, as they relate to us, are intended to identify forward-looking statements. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our financial condition, results of operations, business strategy and financial needs. Actual results may differ materially from those included in these statements due to a variety of factors, including whether: GeoVax is able to obtain acceptable results from ongoing or future clinical trials of its investigational products, GeoVax’s immuno-oncology products and preventative vaccines can provoke the desired responses, and those products or vaccines can be used effectively, GeoVax’s viral vector technology adequately amplifies immune responses to cancer antigens, GeoVax can develop and manufacture its immuno-oncology products and preventative vaccines with the desired characteristics in a timely manner, GeoVax’s immuno-oncology products and preventative vaccines will be safe for human use, GeoVax’s vaccines will effectively prevent targeted infections in humans, GeoVax’s immuno-oncology products and preventative vaccines will receive regulatory approvals necessary to be licensed and marketed, GeoVax raises required capital to complete development, there is development of competitive products that may be more effective or easier to use than GeoVax’s products, GeoVax will be able to enter into favorable manufacturing and distribution agreements, and other factors, over which GeoVax has no control. Further information on our risk factors is contained in our periodic reports on Form 10-Q and Form 10-K that we have filed and will file with the SEC. Any forward-looking statement made by us herein speaks only as of the date on which it is made. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by law. GOVX is a client of Institutional Analyst, publisher of the Biotech Stock Review, which receives a monthly retainer of five-thousand dollars for ongoing progress reporting and news coverage.

GeoVax Labs, Inc. is followed by the analysts listed above. Please note that any opinions, estimates or forecasts regarding GeoVax Labs, Inc.’s performance made by these analysts (and us) are theirs alone and do not represent opinions, forecasts or predictions of GeoVax Labs, Inc. or its management. GeoVax Labs, Inc. does not by its reference below or distribution imply its endorsement of or concurrence with such information, conclusions or recommendations.